10:18 AM EST - Medicenna Therapeutics Corp. : Will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy to be held from October 1 - 4, in Toronto. Medicenna Therapeutics Corp.
shares T.MDNA are trading unchanged at $0.38.
